The complexities and seemingly minor minutiae of patent laws prove vital in a recent decision by the Federal Circuit involving medical device giant, Meril. Meril, a company based in India, had been pursuing FDA approval for their Myval-branded transcatheter heart valves, a product already approved in India and the EU. In the pursuit of this approval, Meril staff attended the 2019 Transcatheter Cardiovascular Therapeutics Conference in San Francisco with the primary goal being recruitment for clinical trial researchers. The company instructed their employees against making any sales or offers within the USA, though it was permitted for other countries. Importantly, a couple of sample products were brought along for potential demonstrations but were not used.
This seemingly mundane detail became pivotal when Edwards Lifesciences, a rival firm, filed a patent infringement lawsuit against Meril. The court found in favor of Meril, with the decision hinging on the interpretation of the safe harbor provision of 35 U.S. Code § 271(e)(1), essentially ruling that Meril’s actions were exempt from patent infringement as they intended the products for FDA approval, which was in accordance with the “safe harbor” law.
However, this decision was not without dissent. Judge Lourie contended the majority’s interpretation of “solely” in the statute, arguing that the incoming samples should have been used solely for the development of information for the FDA for the safe harbor law to apply. Such disagreements over the interpretation of a single word emphasize the complexities of patent law and highlight the need for careful consideration in actions that might intersect with intellectual property rights.
This case offers a clear example for globalized pharmaceutical industry, illustrating how crucial even seemingly small actions can be in patent-related litigation. It is a pointed reminder of the importance of precision in the application of patent law and the precarious balance struck between protecting intellectual properties and fostering innovation.